Stock, pipeline and biotech catalyst intelligence
Market expectations
Street view at a glance
The average target implies 181.7% upsideTargets are estimates—not guarantees—and can change after company updates.Wall Street consensus
BuyBased on 1 analyst opinionsPrice-target range
$4.00Company profile
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.